Clinical trials: Major Bleeding Outcomes
Hemophilia A
Health-Related Quality of Life Outcomes and Bleeding Rates Among Patients With Severe Hemophilia A on Emicizumab
The main purposes of this study are to determine if use of emicizumab prophylaxis treatment reduces number of bleeding episodes, if it improves quality of life of individuals and if improves arthropathy in persons with hemophilia…
- Trial name
- ML43518 (NCT06104826)
- Testing
- Emicizumab
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Newark Beth Israel Medical Center
Severe Postpartum Haemorrhage
Clinical Outcomes of NovoSeven® Treatment in Severe Postpartum Haemorrhage - a Study at the University Hospital of Bern
This non-interventional study will compare the clinical outcomes in women with an event of severe postpartum haemorrhage treated with NovoSeven® to clinical outcomes in women with an event of severe postpartum haemorrhage not…
- Trial name
- NCT04444856
- Testing
- Eptacog alfa (activated), Standard of care
- Where
- Switzerland
- Volunteers
- 225 people
- Sponsor
- Novo Nordisk A/S
Trauma (Including Fractures), Facial Bones Fracture
Haemorrhage From Severe Neck and Facial Injuries - Characteristics, Management and Outcomes
This is a descriptive observational study of trauma patients admitted to the Trauma Unit at the Karolinska University Hospital Solna, Stockholm, Sweden.
- Conditions
- Trauma (Including Fractures), Facial Bones Fracture, Neck Injuries
- Trial name
- NCT07204405
- Volunteers
- 15,000 people
- Sponsor
- Karolinska University Hospital
Trauma, Hemorrhage
Transfusion for Major Haemorrhage in Trauma - Characteristics and Outcomes
Background: Trauma is the leading cause of death in young adults worldwide and the most common causes of mortality are haemorrhage and brain injury.
- Conditions
- Trauma, Hemorrhage, Shock, Traumatic, Acute Coagulopathy
- Trial name
- NCT05573841
- Where
- Sweden
- Volunteers
- 161 people
- Sponsor
- Karolinska University Hospital
Severe Hemophilia A Without Inhibitor, Joint Bleed
Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia A
To outcome between low dose Emicizumab and low dose prophylaxis with FVIII concentration To study pharmacokinetic, side effect of low dose Emicizumab
- Trial name
- NCT06155955
- Testing
- "Emicizumab", "HEMLIBRA®"
- Where
- Thailand
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
Neonatal Thrombocytopenia, Intraventricular Hemorrhage
PRedicting OutcomeS in Preterm nEonates With thromboCyTopenia
Preterm neonates often receive platelet transfusions when their platelet count is low to prevent bleeding. However, it is currently unclear which infants benefit from such transfusions.
- Conditions
- Neonatal Thrombocytopenia, Intraventricular Hemorrhage, Platelet Transfusion
- Trial name
- PROSPECT (NCT06043050)
- Testing
- Platelets
- Where
- 12 sites in Germany, Netherlands and 1 more
- Volunteers
- 1,042 people
- Sponsor
- Leiden University Medical Center